NEFL and myeloid sarcoma: We then thought to assess the strength of correlation between the winning CSF surrogate of MS lesional activity and neurofilament light chain (NfL), a validated marker of axonal damage (Norgren et al., 2004; Teunissen and Khalil, 2012; Gaetani et al., 2019; Alirezaei et al., 2020).